Many patients seeking glucagon-like peptide-1 receptor agonists (GLP-1RAs) turned to compound pharmacies as demand for Eli ...

The Food and Drug Administration on Friday approved Eli Lilly's weight-loss drug Zepbound as a treatment for ...

Undiagnosed or untreated EPI could result in muscle loss since the patient isn’t absorbing the necessary nutrients.

Consumers who take copies of the weight loss drug Zepbound and diabetes drug Mounjaro will need to find a new source for ...

"An MDL that encompassed any potential injury relating to use of these exceedingly popular weight loss drugs might quickly ...

All products are independently selected by our editors. If you buy something, we may earn an affiliate commission.

Some people are not taking weight-loss medications responsibly, the physician says, and don't realize their full implications ...

Eli Lilly just gave investors several reasons to cheer.

The following is a summary of “Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity,” published in the ...

Researchers have achieved impressive results in animal studies with a new weight-loss drug that has no GLP-1-style side ...

CagriSema is a fixed-dose combination of cagrilintide, a long-acting amylin analogue, and semaglutide, a glucagon-like peptide-1 receptor agonist.